Skip to content

Youth Ending the HIV Epidemic

Youth Ending the HIV Epidemic - Automated Directly Observed Therapy Pilot: Improving HIV Care Among Youth

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05789875
Acronym
YEHE
Enrollment
28
Registered
2023-03-29
Start date
2023-01-31
Completion date
2023-09-08
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS, Mobile Health, Young Adults

Brief summary

Young adults have a disproportionately high rate of HIV infection, high rates of attrition at all stages of the HIV care continuum, an increased risk of antiretroviral therapy (ART) nonadherence and virologic failure, and a high probability of disease progression and transmission. Tracking and monitoring objective measures of ART adherence in real time is critical to strategies to support adherence and improve clinical outcomes. However, adherence monitoring often relies on self-reported and retrospective data or requires extra effort from providers to understand adherence patterns, making it difficult for providers to accurately determine how to support their patients in real time. In the proposed interventional study, the investigators aim to pilot test an automated directly observed therapy intervention paired with conditional economic incentives to improve ART adherence among youth living with HIV (YLWH) (18-29 years-old) who have an unsuppressed HIV viral load. Aim 1: Conduct a pilot study to assess feasibility and acceptability of the use of automated directly observed therapy with conditional economic incentives (aDOT-CEI) among YLWH (aged 18-29; N= 30) at AIDS Healthcare Foundation (AHF) clinics in California and Florida. Primary outcomes will be feasibility and acceptability, assessed using predefined feasibility metrics and acceptability surveys at three months. Aim 2: Explore experiences of YLWH and staff/providers with the aDOT-CEI intervention and implementation facilitators and barriers. The investigators will conduct in-depth qualitative interviews with a sample of YLWH from Aim 1 and staff/providers purposively selected from participating AHF clinics to explore intervention experiences, potential influences on ART adherence, individual-level and clinic-level barriers and facilitators to intervention implementation, and suggested refinements for a future efficacy trial. The investigators hypothesize that the aDOT-CEI intervention to improve ART adherence among YLWH will have high feasibility and acceptability.

Detailed description

Automated directly observed therapy (aDOT) is an innovative technology that uses artificial intelligence (AI) with computer vision and deep learning algorithms to track and support adherence through a smartphone. Additionally, aDOT provides a seamless and convenient platform for providing Conditional Economic Incentives (CEIs) because it monitors real-time adherence to automatically determine who can receive incentives. For the design and development of the mobile health app, the investigators have partnered with AiCure to use an existing HIPAA-compliant mobile health app. The investigators will invite YLWH from AIDS Healthcare Foundation (AHF) sites in CA and FL to form the study Youth Advisory Panel (YAP) and seek their input on the AiCure app. The investigators will work with AiCure to implement any required changes to the app that have emerged from formative research. The app will then be piloted with YLWH (aged 18-29; N= 30) who will use the platform for a period of 3 months (Aim 1). The app will record video of the participant taking their HIV medication in order to monitor the participant's medication adherence. Participants will complete online surveys at baseline and 3 months. The investigators will have monthly check-ins with participants which the investigators will assess app use and help increase study engagement. The investigators will measure feasibility and acceptability through app paradata (i.e., app use information) and self-report in surveys (baseline, 3 months). And the investigators will use adherence-related medical record data from AHF to compare against adherence monitored by the AiCure app. Following completion of the pilot, the investigators will conduct in-depth interviews (IDIs) with YLWH and staff /providers purposively selected from participating AHF clinics (Aim 2). Interviews will explore intervention experiences, potential influences on current and long-term ART adherence, unaddressed adherence barriers and the potential benefit of features (e.g., reminders), individual-level and clinic-level barriers and facilitator to intervention implementation, assess ease of use of aDOT-CEI, likes and dislikes, and suggested modifications for a future efficacy trial. This interventional pilot study will assess the feasibility and acceptability of aDOT-CEI and will provide preliminary data to inform an R01 to test the efficacy of aDOT-CEI in addressing disproportionately low viral suppression among YLWH.

Interventions

OTHERaDOT-CEI

For the design and development of the mobile health app, we have partnered with AiCure to use an existing HIPAA-compliant mobile health app. The app will record video of the participant taking their HIV medication in order to monitor the participant's medication adherence and track incentives for this behavior in real-time.

Sponsors

AiCure
CollaboratorINDUSTRY
RTI International
CollaboratorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH
University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 29 Years
Healthy volunteers
No

Inclusion criteria

* 18 to 29 years of age * Have access to a smartphone * Can speak and read English * Client is at an AHF clinic in California or Florida * Client has an unsuppressed HIV viral load at least 3 months post HIV diagnosis * Client is on once daily oral antiretroviral therapy * Consent to participate in the proposed study

Exclusion criteria

* YLWH who are newly HIV diagnosed in the past 3 months * Smartphone is a Samsung galaxy s21 or iPhone 5SE (app is not supported by these phones)

Design outcomes

Primary

MeasureTime frameDescription
Acceptability: Satisfaction With the App+Incentives (Mostly, Very)3 monthsClient satisfaction with the app+incentives. 7-point Likert Scale values from 1-7 with lower values corresponding to least satisfaction and higher values corresponding to greater satisfaction.
Feasibility: Mean Number of Seconds in App Per Day3 monthsMobile app data from the AiCure Application (Paradata) will be used to measure the number of seconds each participant spends in that app each day, thereby calculating the mean number of seconds in app per day per participant.
Feasibility: Mean Percent Doses a Participant May Have Falsified Med-taking3 monthsThe AiCure mobile application platform uses an artificial intelligence or AI platform to recognize dosing patterns recorded by users that do not correspond to what has been defined as 'normal' dosing by the AI. The AI accordingly flags any video recording featuring abnormal dosing for review by the AiCure Video Review team. Upon confirmation of abnormal dosing, the AiCure Video Review team notifies the research coordinator in the form of a Red Alert. Each of these Red Alerts message will be counted as an event of intentional nonadherence, and the mean number of times a participant may have falsified medication taking will be calculated and compared against the number of 'normal' doses.
Acceptability: System Usability Scale (SUS) >68, Considered Above Average and Acceptable3 monthsThe acceptability of the AiCure Mobile application will be through the System Usability Scale (SUS). The intervention was considered acceptable if ≥80% had a SUS score \>68, which is considered above average acceptability.
Acceptability: Client Satisfaction Questionnaire (CSQ-8) Score of ≥17, Considered Above Average and Acceptable3 monthsClient satisfaction will be measured using a Client Satisfaction Questionnaire (CSQ-8). The CSQ-8 is an 8-item scale with higher values indicating higher satisfaction. Acceptability was set as a cutoff of 80% having a score of ≥17, which is the score cutoff considered above average and acceptable for this measure.
Acceptability: Likelihood of Recommending the Study to a Friend (Extremely, Very)3 months.Recommend study to a friend. 7-point Likert Scale of how likely participants are to recommend the study to a friend. The intervention was considered acceptable if ≥80% reported likely or very likely to recommend.
Feasibility: Rate of Participant Retention3 MonthsRate of Participant Retention will be calculated as the percent of those who were retained in the study and completed the final survey.
Feasibility: Mean Logins Per Week3 monthsMobile app data from the AiCure Application (paradata) will be used to measure the number of participant logins per week and thereby calculate mean logins per participant per week.

Secondary

MeasureTime frameDescription
Median Self-Reported Adherence Score at Study Exit3 monthsThe preliminary effect on ART adherence will be measured through self-report using a 3-item scale that has been previously validated. Questions ask about frequency of missed medications in the last 30 days, adherence frequency in the last 30 days, and adherence rating in the last 30 days. Reponses to the 3 questions were transformed to a 0-100 scale, with higher scores indicating better adherence. A summary score was calculated as the mean of the 3 individual items.
Monitoring of Behavior: Number of Seconds in App3 monthsNumber of seconds in app collected using mobile app data (paradata) from AiCure platform.
Monitoring of Behavior: Ease of Use3 monthsHow easy/difficult was it to use your personal phone; use adherence monitoring; receive incentives? Measured using a 7-point Likert Scale ranging from easy to difficult. Higher values correspond to greater ease of use, lower values correspond to greater difficulty.
Monitoring of Behavior: Frequency of App Related Issues3 monthsDid you ever have trouble accessing app, using adherence monitoring, receiving reminders, receiving incentives, or finding a private place? 7-point Likert of frequency ranging from often to never with high value corresponding to app related issues occurring with greater frequency and lower value corresponding to app related issues issues occurring with lesser frequency.
Mean Percent Adherence Over the Study Period (Excluding Those Lost to Follow up)3 monthsAdherence data will be abstracted from the automated directly observed therapy platform within the AiCure mobile health application. Percent adherence will be calculated as the percentage of days over the study period that participants recorded taking their medication within the app.

Countries

United States

Participant flow

Participants by arm

ArmCount
Intervention
All YLWH who choose to enroll in the study will receive access to AiCure, the mobile health application. The participants will be asked to use the app for 3 months, during which the investigators will assess the feasibility and acceptability of AiCure. aDOT-CEI: For the design and development of the mobile health app, we have partnered with AiCure to use an existing HIPAA-compliant mobile health app. The app will record video of the participant taking their HIV medication in order to monitor the participant's medication adherence and track incentives for this behavior in real-time.
28
Total28

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up6

Baseline characteristics

CharacteristicIntervention
Age, Continuous28 years
Ethnicity (NIH/OMB)
Hispanic or Latino
12 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
16 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Financial Situation15 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
11 Participants
Race (NIH/OMB)
More than one race
4 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
Race (NIH/OMB)
White
10 Participants
Region of Enrollment
United States
28 participants
Sex: Female, Male
Female
1 Participants
Sex: Female, Male
Male
27 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 28
other
Total, other adverse events
0 / 28
serious
Total, serious adverse events
0 / 28

Outcome results

Primary

Acceptability: Client Satisfaction Questionnaire (CSQ-8) Score of ≥17, Considered Above Average and Acceptable

Client satisfaction will be measured using a Client Satisfaction Questionnaire (CSQ-8). The CSQ-8 is an 8-item scale with higher values indicating higher satisfaction. Acceptability was set as a cutoff of 80% having a score of ≥17, which is the score cutoff considered above average and acceptable for this measure.

Time frame: 3 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
InterventionAcceptability: Client Satisfaction Questionnaire (CSQ-8) Score of ≥17, Considered Above Average and Acceptable22 Participants
Primary

Acceptability: Likelihood of Recommending the Study to a Friend (Extremely, Very)

Recommend study to a friend. 7-point Likert Scale of how likely participants are to recommend the study to a friend. The intervention was considered acceptable if ≥80% reported likely or very likely to recommend.

Time frame: 3 months.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
InterventionAcceptability: Likelihood of Recommending the Study to a Friend (Extremely, Very)16 Participants
Primary

Acceptability: Satisfaction With the App+Incentives (Mostly, Very)

Client satisfaction with the app+incentives. 7-point Likert Scale values from 1-7 with lower values corresponding to least satisfaction and higher values corresponding to greater satisfaction.

Time frame: 3 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
InterventionAcceptability: Satisfaction With the App+Incentives (Mostly, Very)20 Participants
Primary

Acceptability: System Usability Scale (SUS) >68, Considered Above Average and Acceptable

The acceptability of the AiCure Mobile application will be through the System Usability Scale (SUS). The intervention was considered acceptable if ≥80% had a SUS score \>68, which is considered above average acceptability.

Time frame: 3 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
InterventionAcceptability: System Usability Scale (SUS) >68, Considered Above Average and Acceptable18 Participants
Primary

Feasibility: Mean Logins Per Week

Mobile app data from the AiCure Application (paradata) will be used to measure the number of participant logins per week and thereby calculate mean logins per participant per week.

Time frame: 3 months

Primary

Feasibility: Mean Number of Seconds in App Per Day

Mobile app data from the AiCure Application (Paradata) will be used to measure the number of seconds each participant spends in that app each day, thereby calculating the mean number of seconds in app per day per participant.

Time frame: 3 months

ArmMeasureValue (MEAN)
InterventionFeasibility: Mean Number of Seconds in App Per Day28 seconds/day
Primary

Feasibility: Mean Percent Doses a Participant May Have Falsified Med-taking

The AiCure mobile application platform uses an artificial intelligence or AI platform to recognize dosing patterns recorded by users that do not correspond to what has been defined as 'normal' dosing by the AI. The AI accordingly flags any video recording featuring abnormal dosing for review by the AiCure Video Review team. Upon confirmation of abnormal dosing, the AiCure Video Review team notifies the research coordinator in the form of a Red Alert. Each of these Red Alerts message will be counted as an event of intentional nonadherence, and the mean number of times a participant may have falsified medication taking will be calculated and compared against the number of 'normal' doses.

Time frame: 3 months

ArmMeasureValue (MEAN)
InterventionFeasibility: Mean Percent Doses a Participant May Have Falsified Med-taking2 % of doses
Primary

Feasibility: Rate of Participant Retention

Rate of Participant Retention will be calculated as the percent of those who were retained in the study and completed the final survey.

Time frame: 3 Months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
InterventionFeasibility: Rate of Participant Retention22 Participants
Secondary

Mean Percent Adherence Over the Study Period (Excluding Those Lost to Follow up)

Adherence data will be abstracted from the automated directly observed therapy platform within the AiCure mobile health application. Percent adherence will be calculated as the percentage of days over the study period that participants recorded taking their medication within the app.

Time frame: 3 months

ArmMeasureValue (MEAN)
InterventionMean Percent Adherence Over the Study Period (Excluding Those Lost to Follow up)72.7 percentage of days adherent
Secondary

Median Self-Reported Adherence Score at Study Exit

The preliminary effect on ART adherence will be measured through self-report using a 3-item scale that has been previously validated. Questions ask about frequency of missed medications in the last 30 days, adherence frequency in the last 30 days, and adherence rating in the last 30 days. Reponses to the 3 questions were transformed to a 0-100 scale, with higher scores indicating better adherence. A summary score was calculated as the mean of the 3 individual items.

Time frame: 3 months

ArmMeasureValue (MEDIAN)
InterventionMedian Self-Reported Adherence Score at Study Exit82.7 overall adherence score
Secondary

Monitoring of Behavior: Ease of Use

How easy/difficult was it to use your personal phone; use adherence monitoring; receive incentives? Measured using a 7-point Likert Scale ranging from easy to difficult. Higher values correspond to greater ease of use, lower values correspond to greater difficulty.

Time frame: 3 months

Secondary

Monitoring of Behavior: Frequency of App Related Issues

Did you ever have trouble accessing app, using adherence monitoring, receiving reminders, receiving incentives, or finding a private place? 7-point Likert of frequency ranging from often to never with high value corresponding to app related issues occurring with greater frequency and lower value corresponding to app related issues issues occurring with lesser frequency.

Time frame: 3 months

Secondary

Monitoring of Behavior: Number of Seconds in App

Number of seconds in app collected using mobile app data (paradata) from AiCure platform.

Time frame: 3 months

ArmMeasureValue (MEAN)
InterventionMonitoring of Behavior: Number of Seconds in App28 seconds/day

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026